Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases.
Nicholas H B SchräderJ C DuipmansB MolenbuurA P WolffMarcel F JonkmanPublished in: The British journal of dermatology (2018)
Epidermolysis bullosa (EB) is a genetic blistering disorder characterized by intense pain related to disease pathology and care-based interventions. Opioid-based therapies underpin pain care in EB; however, they are unable to provide adequate analgesia in a significant proportion of patients. Cannabinoid-based medicines (CBMs) have been studied increasingly for pain conditions of various aetiologies and pose as a novel dimension for pain care in EB. We present three patients with EB who were prescribed pharmaceutical-grade sublingually administered CBMs comprising tetrahydrocannabinol and cannabidiol. All three patients reported improved pain scores, reduced pruritus and reduction in overall analgesic drug intake.
Keyphrases
- pain management
- chronic pain
- neuropathic pain
- end stage renal disease
- healthcare
- palliative care
- ejection fraction
- newly diagnosed
- chronic kidney disease
- quality improvement
- peritoneal dialysis
- emergency department
- spinal cord injury
- prognostic factors
- gene expression
- spinal cord
- weight loss
- dna methylation
- body mass index
- weight gain
- anti inflammatory
- adverse drug